Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,209,504 papers from all fields of science
Search
Sign In
Create Free Account
OGX-011
Known as:
ISIS 112989
A mixed-backbone antisense oligodeoxynucleotide with chemosensitizing properties. OGX-011 inhibits testosterone-repressed prostate message-2 (TRPM-2…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (2)
Thionucleotides
clusterin antisense oligonucleotide
Narrower (1)
custirsen
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Small heat shock proteins in cancer therapy and prognosis.
A. Zoubeidi
,
M. Gleave
The international journal of biochemistry & cell…
2012
Corpus ID: 6374412
Review
2011
Review
2011
New therapies for castration-resistant prostate cancer: efficacy and safety.
H. Beltran
,
T. Beer
,
+8 authors
I. Tannock
European urology
2011
Corpus ID: 42938122
Highly Cited
2011
Highly Cited
2011
Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after…
F. Saad
,
S. Hotte
,
+10 authors
E. Winquist
Clinical Cancer Research
2011
Corpus ID: 207708985
Purpose: Clusterin (CLU) is an antiapoptotic, stress-induced protein conferring treatment resistance when overexpressed. This…
Expand
Highly Cited
2010
Highly Cited
2010
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
K. Chi
,
S. Hotte
,
+8 authors
E. Eisenhauer
Journal of clinical oncology : official journal…
2010
Corpus ID: 207025761
PURPOSE To determine the clinical activity of OGX-011, an antisense inhibitor of clusterin, in combination with docetaxel…
Expand
Highly Cited
2008
Highly Cited
2008
A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer
K. Chi
,
L. Siu
,
+9 authors
E. Eisenhauer
Clinical Cancer Research
2008
Corpus ID: 31998919
Purpose: Clusterin is a cytoprotective chaperone protein that promotes cell survival and confers broad-spectrum treatment…
Expand
Highly Cited
2008
Highly Cited
2008
Clusterin knockdown using the antisense oligonucleotide OGX‐011 re‐sensitizes docetaxel‐refractory prostate cancer PC‐3 cells to chemotherapy
R. Sowery
,
B. Hadaschik
,
+4 authors
M. Gleave
BJU international
2008
Corpus ID: 36387064
To characterize changes in secretory clusterin (sCLU) expression in prostate cancer cells after treatment with docetaxel and to…
Expand
Review
2008
Review
2008
Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer
K. Chi
,
A. Zoubeidi
,
M. Gleave
2008
Corpus ID: 72504146
Background: Clusterin is a stress-induced cytoprotective chaperone protein, regulated by HSF1, and functions similarly to a small…
Expand
Highly Cited
2007
Highly Cited
2007
Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100
R. Yu
,
Tae-Won Kim
,
A. Hong
,
Tanya A Watanabe
,
H. Gaus
,
R. Geary
Drug Metabolism and Disposition
2007
Corpus ID: 23718269
The pharmacokinetics of a 2′-O-(2-methoxyethyl)-modified oligonucleotide, ISIS 301012 [targeting human apolipoprotein B-100 (apoB…
Expand
Highly Cited
2005
Highly Cited
2005
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.
K. Chi
,
E. Eisenhauer
,
+5 authors
M. Gleave
Journal of the National Cancer Institute
2005
Corpus ID: 22514807
BACKGROUND Clusterin is a cytoprotective chaperone protein that promotes cell survival and confers broad-spectrum treatment…
Expand
Review
2005
Review
2005
Antisense therapy for cancer
M. Gleave
,
B. Monia
Nature Reviews Cancer
2005
Corpus ID: 8673630
Improved understanding of the molecular mechanisms that mediate cancer progression and therapeutic resistance has identified many…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE